Trial Profile
Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Zirconium-89 cetuximab (Primary) ; Panitumumab
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms IMPACT-CRC
- 07 Mar 2021 Status changed from recruiting to discontinued.
- 05 Oct 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.
- 05 Oct 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.